Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

(+)-JQ1 (Item No. 11187) binds to the acetyl-lysine recognition pocket of bromodomains 1 and 2 on BRD4 with Kd values of ~50 and 90 nM, respectively.1 This displaces BRD4 from nuclear chromatin in cells, inducing differentiation and growth arrest in midline carcinoma cells.1 CPI-203 is a primary amide analog of (+)-JQ1 which has shown superior bioavailability with oral or i.p. administration.2 It is comparable or superior to (+)-JQ1 in inhibiting BRD4 binding and action in vitro or in cells.2,3 CPI-203 arrests the growth of leukemic T cells in vitro (EC50 = 91 nM) and rapidly suppresses leukemia burden in mice.2
WARNING This product is not for human or veterinary use.
1. Selective inhibition of BET bromodomains. Nature 468(7327), 1067-1073 (2010).
2. The ubiquitin ligase FBXW7 modulates leukemia-
3. BRD4 is an atypical kinase that phosphorylates serine 2 of the RNA polymerase II carboxy-